Spero Therapeutics (SPRO) Retained Earnings (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Retained Earnings came in at -$458.3 million in Q1 2026, up 3.21% YoY from -$444.0 million in Q1 2025, and down 1.6% on a QoQ basis from -$451.1 million in Q4 2025.
Spero Therapeutics (SPRO) Retained Earnings (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Retained Earnings data on file, last reported at -$458.3 million in Q1 2026.
- Quarterly Retained Earnings rose 3.21% year-over-year to -$458.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$458.3 million (up 3.21% YoY) and the FY2025 annual result came in at -$451.1 million, up 1.86% from the prior year.
- Retained Earnings fell to -$458.3 million in Q1 2026, from -$451.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$391.1 million in Q4 2023 to a low of -$482.6 million in Q3 2025.
- A 5-year average of -$439.2 million and a median of -$440.6 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings plunged 34.74% — and 2023, when it climbed 5.51%.
- Tracing SPRO's Retained Earnings over 5 years: stood at -$413.9 million in 2022, then rose by 5.51% to -$391.1 million in 2023, then retreated by 17.53% to -$459.6 million in 2024, then grew by 1.86% to -$451.1 million in 2025, then retreated by 1.6% to -$458.3 million in 2026.
- The last three Retained Earnings figures came in at -$458.3 million (Q1 2026), -$451.1 million (Q4 2025), and -$482.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 4.38 Bn |
| 10 | Spero Therapeutics | 71.59 Mn | 20.82 Mn | - | -467.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -467.82 Mn |
| Mar 31, 2026 | -458.30 Mn |
| Dec 31, 2025 | -451.07 Mn |
| Sep 30, 2025 | -482.59 Mn |
| Jun 30, 2025 | -475.20 Mn |
| Mar 31, 2025 | -473.50 Mn |
| Dec 31, 2024 | -459.64 Mn |
| Sep 30, 2024 | -438.75 Mn |
| Jun 30, 2024 | -421.60 Mn |
| Mar 31, 2024 | -403.70 Mn |
| Dec 31, 2023 | -391.07 Mn |
| Dec 31, 2022 | -413.88 Mn |
| Sep 30, 2022 | -440.65 Mn |
| Mar 31, 2022 | -400.30 Mn |
| Dec 31, 2021 | -367.46 Mn |
| Sep 30, 2021 | -338.22 Mn |
| Jun 30, 2021 | -315.70 Mn |
| Mar 31, 2021 | -297.10 Mn |
| Dec 31, 2020 | -277.71 Mn |
| Sep 30, 2020 | -259.10 Mn |